(Total Views: 622)
Posted On: 07/14/2021 2:10:43 PM
Post# of 145247
Here we go again:
Quote:
At IncellDx, we’re working to target these pathways therapeutically. We have filed patents to cover the targeting of the CCL5/CCR5 and fractalkine pathways in PASC," said Dr. Patterson.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)